Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$0.36
+1.7%
$0.41
$0.24
$2.53
$21.09M0.91906,238 shs221,731 shs
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
$13.89
$2.01
$4.26
$185.20M0.2282,405 shs435,164 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.31
-4.8%
$5.83
$1.89
$11.64
$54.82M1.34853,122 shs616,826 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-12.5%
$0.00
$0.00
$0.02
$772K0.9894,175 shs4,373 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
0.00%-8.21%-12.31%+3.87%-79.29%
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
0.00%0.00%0.00%0.00%0.00%
INmune Bio, Inc. stock logo
INMB
INmune Bio
0.00%+4.76%-62.07%-66.76%-70.05%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-41.67%-36.36%+40.00%-83.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioAtla, Inc. stock logo
BCAB
BioAtla
1.6282 of 5 stars
3.31.00.00.00.62.50.6
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/AN/AN/AN/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.5772 of 5 stars
3.31.00.00.01.11.70.6
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.5875 of 5 stars
0.01.00.04.30.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAtla, Inc. stock logo
BCAB
BioAtla
2.50
Moderate Buy$5.001,296.65% Upside
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
0.00
N/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.57
Moderate Buy$18.40698.26% Upside
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INMB, SRNE, BCAB, and GRPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $8.00
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
6/30/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAtla, Inc. stock logo
BCAB
BioAtla
$11M1.90N/AN/A$0.25 per share1.43
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/AN/AN/AN/A$3.15 per shareN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K5,435.19N/AN/A$1.45 per share1.59
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.01N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAtla, Inc. stock logo
BCAB
BioAtla
-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
-$124.65M-$2.23N/AN/AN/AN/A-33.12%-27.96%N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A

Latest INMB, SRNE, BCAB, and GRPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.29N/AN/AN/AN/AN/A
8/7/2025Q2 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.37N/AN/AN/AN/AN/A
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
5/6/2025Q1 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.28-$0.29-$0.01-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
2.35
2.35
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/A
39.20
39.20
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
77.23%
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
54.32%
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
11.50%
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
38.40%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAtla, Inc. stock logo
BCAB
BioAtla
6058.42 million51.70 millionOptionable
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
658.24 million35.87 millionNot Optionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1023.58 million15.17 millionOptionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Therapeutics Inc (SRNE) - Investing.com
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
Sorrento Therapeutics Inc (SRNE)
Sorrento Therapeutics Inc SRNE
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
Sorrento Therapeutics
5 Sanders Cove, Sorrento WA 6020

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAtla stock logo

BioAtla NASDAQ:BCAB

$0.36 +0.01 (+1.70%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Graphite Bio stock logo

Graphite Bio NASDAQ:GRPH

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.31 -0.12 (-4.75%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0014 0.00 (-12.50%)
As of 10:22 AM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.